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Abstract
Objective. According to the recent theories on the ovarian cancer origin, any pro-
tective effect of tubal ligation may vary with histologic subtype of ovarian cancer.
Furthermore, bilateral salpingectomy may represent an opportunity for surgical
prevention of serous ovarian cancer. Design. Nationwide register-based case–
control study. Setting. Denmark during 1982–2011. Population. Cases were all
Danish women diagnosed with epithelial ovarian cancer (n = 13 241) or border-
line ovarian tumor (n = 3605) in the study period. Age-matched female popula-
tion controls were randomly selected by risk set sampling. We required that cases
and controls have no previous cancer and that controls have no previous bilateral
oophorectomy. Methods. Conditional logistic regression was used to estimate
odds ratios and 95% confidence intervals, adjusting for potential confounders.
Main outcome measures. Epithelial ovarian cancer and borderline ovarian tumors
stratified according to histology. Results. Tubal ligation reduced overall epithelial
ovarian cancer risk (odds ratios 0.87; 95% confidence interval 0.78–0.98). We
observed significant risk variation according to histology (p = 0.003) with the
strongest risk reductions associated with endometrioid cancer (odds ratios 0.66;
95% confidence interval 0.47–0.93) and epithelial ovarian cancer of “other” his-
tology (odds ratios 0.60; 95% confidence interval 0.43–0.83). Tubal ligation was
not associated with risk of borderline ovarian tumors. Finally, bilateral salpingec-
tomy reduced epithelial ovarian cancer risk by 42% (odds ratios 0.58; 95% confi-
dence interval 0.36–0.95). Conclusions. We confirmed that tubal ligation reduces
the risk of epithelial ovarian cancer and particularly endometrioid cancer. To our
knowledge, this is the first observational publication to report on salpingectomy
and ovarian cancer risk and our promising findings warrant further investigation.
Abbreviations: CI, confidence interval; ICD, International Classification of
Disease; ICD-O-3, ICD for Oncology; OR, odds ratio.
Introduction
Traditionally, epithelial ovarian cancer was thought to
originate from the ovarian surface epithelium (1). How-
ever, more recently it has been suggested that the origin
is extra-ovarian and that the ovary is involved subse-
quently (2,3). According to these new theories, serous
Key Message
Consistent with recent theories on ovarian cancer ori-
gin, we observed that tubal ligation reduced the risk
of particularly endometrioid ovarian cancer. Albeit
with limited statistical precision; bilateral salpingecto-
my reduced the risk of epithelial ovarian cancer by
approximately 40%.
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tumors, the most common histologic subtype of epithelial
ovarian cancer, may develop from the Fallopian tube
(3,4). Endometrioid and clear cell tumors may originate
from the endometrium, whereas mucinous tumors may
arise from the tubal–mesothelial junction where the fimb-
riae touch the peritoneum (3).
Recent theories on the origin of ovarian cancer add to
our understanding of the suggested inverse association
between tubal ligation and ovarian cancer risk (5–7). If
tubal ligation mechanically prevents the migration of
endometrial tissue passing through the Fallopian tube,
one would expect the largest risk reduction for endomet-
rioid and clear cell ovarian cancers (7,8). Subtype-specific
effects of tubal ligation compatible with these theories
have recently been observed in two meta-analyses (5,6)
and two large case–control studies (7,9). However,
although the existing literature on the association between
tubal ligation and ovarian cancer risk is extensive, all
studies except for two (10,11) have been based on self-
reporting, implying a risk of recall bias. Furthermore, if
the Fallopian tube is the site of origin of serous ovarian
cancer, bilateral salpingectomy may represent a potential
opportunity for surgical prevention of serous ovarian can-
cer with preservation of the ovarian hormone production
(12). To our knowledge, no previous publication has
presented observational data on the association between
salpingectomy and ovarian cancer risk.
To further elucidate the role of tubal ligation and sal-
pingectomy in the etiology of epithelial ovarian cancer,
we conducted a large register-based case–control study
including all women in Denmark diagnosed with epithe-
lial ovarian cancer or borderline ovarian tumor in the
period 1982–2011. Analyses were stratified according to
histologic subtype, and potential effect modification was
explored by timing of tubal ligation and other case char-
acteristics.
Material and methods
Since 1968, all citizens in Denmark have been assigned a
unique personal identification number, comprising infor-
mation on date of birth and gender, registered in the
Civil Registration System (13), which also contains infor-
mation on dates of death, and migration to and from
Denmark. Using the personal identification numbers as
key identifiers it is possible to ensure correct linkages
between registries. Our case–control study was nested in
the entire Danish female population, using data from the
Civil Registration System and several other nationwide
registries including the Danish Cancer Registry, the
Pathology Data Bank, the National Patient Register, the
Danish Prescription Registry, and the Danish Fertility
Database.
The Danish Cancer Registry (14) has accurate and
almost complete data on incident cancer cases in Den-
mark since 1943. Cancer diagnoses are recorded according
to the International Classification of Diseases, version 10
(ICD-10) and the ICD for Oncology (ICD-O-3) for
topography and morphology codes. The Danish Pathology
Data Bank (15) contains detailed information on cytologic
and histologic diagnoses performed at pathology depart-
ments in Denmark. The Pathology Data Bank was estab-
lished in 1997, but the majority of pathology departments
have transferred information on diagnoses from 1997
and back to 1978. The National Patient Register (16)
holds information on virtually all diagnoses and surgical
procedures performed at hospitals since 1977, and on
outpatient visits since 1995. Diagnoses are coded accord-
ing to the ICD-8 from 1977 to 1993, and ICD-10 from
1994 onwards. Surgical procedures are classified according
to the Danish Classification of Surgical Procedures and
Therapies until the end of 1995 and thereafter according
to the Nordic Classification of Surgical Procedures. The
Danish Prescription Registry (17) includes information on
all prescription drugs dispensed at pharmacies in
Denmark since 1995 classified by the Anatomical Thera-
peutic Chemical Index (18). The Danish Fertility Database
(19) contains data on reproductive variables for all women
in Denmark aged 13–49 years in 1980 and onwards.
Detailed information on codes used to identify cases,
tubal ligation, unilateral and bilateral salpingectomy, and
potential confounders are listed in the Supporting infor-
mation (Table S1).
Eligible cases were all women in Denmark with a first
diagnosis of histologically verified epithelial ovarian can-
cer or borderline ovarian tumor during 1982–2011. We
further required that women were 30–84 years of age at
diagnosis, were resident in Denmark on date of diagnosis
(index date), and with no previous cancer (except for
nonmelanoma skin cancer). Cases were classified accord-
ing to histology of epithelial ovarian cancer or borderline
ovarian tumor, that is, serous, endometrioid, mucinous,
clear cell, and “other” subtypes (for example Brenner and
squamous cell tumors).
For each case, we randomly selected 15 female popula-
tion controls, matched on date of birth (1 month),
from the Civil Registration System (13) using risk-set
sampling (20). Hence, controls were alive and at risk of a
first cancer (except nonmelanoma skin cancer) at the
time the corresponding case was diagnosed, and women
were eligible as controls before they became cases. The
controls fulfilled the same selection criteria as cases and,
in addition, we excluded controls with previous bilateral
oophorectomy or salpingo-oophorectomy.
Information on tubal ligation and salpingectomy
(unilateral and bilateral) was obtained from the Patient
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Register (16), which also provided information on hyster-
ectomy, endometriosis, pelvic inflammatory disease, and
infertility. Infertility was defined as the diagnosis in the
Patient Register and/or use of fertility drugs (the Pre-
scription Registry). We disregarded all surgical proce-
dures, hospital diagnoses and drug use in the year before
index date. We calculated parity based on information
from the Fertility Database (19) and classified cases and
controls according to number of births at 1 year before
index date, i.e. 0 (nulliparous), 1, 2 and ≥3.
Information on use of oral contraceptives and hor-
mone replacement therapy was obtained solely from the
Prescription Registry (17) and therefore these variables
were only available from 1995. Finally, for women born
after 1953 we were able to assess family history of ovarian
or breast cancer among their sisters and mothers by link-
ing the Civil Registration System (13) and the Danish
Cancer Registry (14).
Statistical analysis
The association between tubal ligation and risk of epithe-
lial ovarian cancer or borderline ovarian tumors was esti-
mated using conditional logistic regression by estimating
age- and multivariable-adjusted odds ratios (ORs) and
two-sided 95% confidence intervals (CIs). Analyses were
performed for epithelial tumors overall and for each of
the histologic subtypes. Although for borderline ovarian
tumors, numbers permitted analyses of serous and
mucinous tumors only. Confounding factors were selected
a priori based on the literature and availability and
included age, parity, infertility, endometriosis, pelvic
inflammatory disease and hysterectomy. In a sub-analysis
including exclusively women born after 1953, we were
able to further adjust for a family history of ovarian or
breast cancer, and use of oral contraceptives and hor-
mone replacement therapy.
We also performed analyses to estimate potential effect
modification by age at tubal ligation (continuously and
categorized as ≤35 and >35 years), time since tubal liga-
tion (continuously and divided into 1–9, 10–19,
≥20 years), and year of tubal ligation (continuously). Year
of tubal ligation reflects changes or improvements in the
surgical procedure over time. The variable was modeled
only continuously because we had no information on cal-
endar periods for marked changes in the tubal ligation
procedure to have occurred in Denmark during our study
period (21,22).
Potential effect measure modification was estimated by
including interaction terms between tubal ligation and
histologic subtype, endometriosis, infertility, pelvic
inflammatory disease, parity (nulliparous and ≥1), and
age at diagnosis of ovarian cancer (≤50 years and
>50 years), respectively. We furthermore compared the
effects of tubal ligation for the nonserous histologic sub-
types of ovarian cancer with the effect of tubal ligation
for serous ovarian cancer by means of Wald tests. The
association between unilateral and bilateral salpingectomy
and risk of epithelial ovarian cancer was estimated by
conditional logistic regression. Due to limited statistical
power, this analysis was adjusted only for age, parity, and
tubal ligation.
All statistical tests were likelihood ratio tests performed
using the statistical software R, version 3.0.2. A signifi-
cance level of 5% was applied. The data were handled
anonymously and the study was approved by the Danish
Data Protection Agency (file number 2013-41-1883), and
Statens Serum Institute and Statistics Denmark (file num-
ber 704327).
Results
We identified a total of 13 241 cases with epithelial ovar-
ian cancer and 3605 cases with borderline ovarian tumors
during 1982–2011. Table 1 shows characteristics of cases
and age-matched controls. The majority of the women
with ovarian cancer were over 50 years old at diagnosis
(82.1%) and serous tumors constituted the most common
histologic subtype (46.5%). Tubal ligation was slightly
more common among controls compared with ovarian
cancer cases (3.2% vs. 2.6%). In contrast, ovarian cancer
cases were more likely than controls to be nulliparous
(38.4% vs. 33.7%) and have a history of infertility (1.9%
vs. 1.2%).
Among cases with borderline ovarian tumors, 45.9%
were 50 years or younger at diagnosis. Most tumors were
either serous (46.6%) or mucinous (49.1%). The preva-
lence of tubal ligation was similar among borderline cases
and controls (5.3% and 5.6%), whereas more cases than
controls were nulliparous (28.3% vs. 22.0%) and had a his-
tory of endometriosis (2.1% vs. 1.2%), infertility (5.5% vs.
3.4%), or pelvic inflammatory disease (8.0% vs. 5.3%).
Epithelial ovarian cancer
Tubal ligation significantly reduced the risk of overall epi-
thelial ovarian cancer (OR = 0.87; 95% CI 0.78–0.98)
(Table 2). The risk estimate was not changed materially
among women born after 1953 after additional adjust-
ment for a family history of ovarian and breast cancer,
use of oral contraceptives, and hormone replacement
therapy (data not shown).
We observed a significant variation in risk according to
histologic subtype of epithelial ovarian cancer
(p = 0.003). The strongest risk reductions associated with
tubal ligation were observed for endometrioid tumors
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(OR = 0.66; 95% CI 0.47–0.93) and epithelial ovarian
cancer of “other” histology (OR = 0.60; 95% CI 0.43–
0.83) (Table 2). In the age-adjusted analysis, data also
indicated that tubal ligation may decrease the risk of ser-
ous and clear cell ovarian cancer, but after adjustment for
potentially confounding factors, the association attenu-
ated. In contrast to the nonmucinous subtypes of epithe-
lial ovarian cancer, we observed a nonsignificantly
increased risk of mucinous ovarian cancer associated with
tubal ligation (OR = 1.25; 95% CI 0.94–1.67).
Compared with serous ovarian cancer, the protective
effect of tubal ligation was significantly larger for endo-
metrioid ovarian cancer (p = 0.047) and epithelial ovar-
ian cancer of “other” histology (p = 0.018), whereas the
effect of tubal ligation for clear cell tumors did not differ
significantly from that for serous tumors (p = 0.880).
Lastly, the OR of tubal ligation associated with risk of
mucinous ovarian cancer seemed to be larger compared
with the OR associated with serous ovarian cancer
(p = 0.052) (data not shown).
The risk of overall epithelial ovarian cancer did
not seem to vary with time since tubal ligation (p-value
for trend = 0.759), age at tubal ligation (p-value for
trend = 0.551) or year of tubal ligation (p-value for
trend = 0.301) (Table 3). Based on small numbers, we
observed no consistent pattern in timing of tubal ligation
with regard to risk for each of the histologic subtypes of
epithelial ovarian cancer. Risk of endometrioid ovarian
cancer was halved among women who had tubal ligation
performed at a younger age (OR = 0.49; 95% CI 0.24–
1.00). For epithelial ovarian cancer of “other” histology,
we found significantly reduced OR associated with tubal
ligation performed at 20 years or longer ago (OR = 0.47;
95% CI 0.26–0.87) and irrespective of age at tubal liga-
tion (≤35 years: OR = 0.51; 95% CI 0.26–1.00; >35 years:
OR = 0.63; 95% CI 0.43–0.91).
We observed no effect modification by endometriosis,
infertility, pelvic inflammatory disease, parity or age at
diagnosis on the association between tubal ligation and
risk of epithelial or serous ovarian cancer, and the data
Table 1. Characteristics of women with epithelial ovarian cancer and borderline ovarian tumors and matching controls.
Characteristics
Epithelial ovarian cancer Borderline ovarian tumors
Cases (n = 13 241) Controls (n = 194 689) Cases (n = 3605) Controls (n = 53 322)
n % n % n % n %
Histologic subtype
Serous 6157 46.5 – – 1679 46.6 – –
Mucinous 1414 10.7 – – 1770 49.1 – –
Endometrioid 1713 12.9 – – 44 1.2 – –
Clear cell 633 4.8 – – 7 0.2 – –
“Other” 3324 25.1 – – 105 2.9 – –
Age at diagnosis/index date (years)
30–40 535 4.0 8042 4.1 687 19.1 10 296 19.3
41–50 1842 13.9 27 452 14.1 966 26.8 14 400 27.0
51–60 3172 24.0 46 590 23.9 865 24.0 12 717 23.8
61–70 3883 29.3 56 734 29.1 635 17.6 9283 17.4
71–80 3123 23.6 45 744 23.5 360 10.0 5279 9.9
>80 686 5.2 10 127 5.2 92 2.6 1347 2.5
Parity
Nulliparous 5085 38.4 65 649 33.7 1020 28.3 11 716 22.0
One 2624 19.8 36 124 18.6 746 20.7 9664 18.1
Two 3497 26.4 55 850 28.7 1224 34.0 20 056 37.6
Three or more 2035 15.4 37 066 19.0 615 17.1 11 886 22.3
Tubal ligation
Yes 345 2.6 6201 3.2 191 5.3 2989 5.6
Hysterectomy
Yes 738 5.6 10 147 5.2 216 6.0 2868 5.4
Endometriosis
Yes 147 1.1 1667 0.9 75 2.1 645 1.2
Pelvic inflammatory disease
Yes 444 3.4 5780 3.0 287 8.0 2852 5.3
Infertility
Yes 258 1.9 2385 1.2 198 5.5 1807 3.4
ª 2014 Nordic Federation of Societies of Obstetrics and Gynecology, Acta Obstetricia et Gynecologica Scandinavica 94 (2015) 86–94 89
C. Madsen et al. Tubal ligation and ovarian cancer risk
did not allow meaningful evaluation of the nonserous his-
tologic subtypes (data not shown).
Finally, the potential association between salpingectomy
and ovarian cancer risk was examined (Table 4). The
analysis was based on few exposed cases. However, we
found that bilateral salpingectomy was associated with a
42% decreased risk of epithelial ovarian cancer
(OR = 0.58; 95% CI 0.36–0.95). We also observed an
inverse association between unilateral salpingectomy and
ovarian cancer, but the risk reduction was smaller and
nonsignificant (OR = 0.90; 95% CI 0.72–1.12).
Epithelial borderline ovarian tumors
Tubal ligation was not associated with the risk of overall
epithelial borderline ovarian tumors (OR = 1.03; 95% CI
0.89–1.21) or with borderline tumors of serous
(OR = 1.00; 95% CI 0.80–1.26) or mucinous (OR = 1.04;
95% CI 0.83–1.30) histology (Table 5). Risk estimates did
not change when the analysis was restricted to women
born after 1953 with further adjustment for a family his-
tory of ovarian and breast cancer, use of oral contracep-
tives, and hormone replacement therapy (data not
shown).
For epithelial borderline ovarian tumors, we also
investigated potential effect modification by timing of
tubal ligation. We observed no difference in risk esti-
mates according to time since tubal ligation (p-value
for trend = 0.874), age at tubal ligation (p-value for
trend = 0.557), and year of tubal ligation (p-value for
trend = 0.166). Similar analyses were performed for
serous and mucinous borderline ovarian tumors, and we
observed no differences in risk according to timing of
tubal ligation. Moreover, the association between tubal
ligation and risk of epithelial borderline ovarian tumors
was not affected by endometriosis, infertility, pelvic
inflammatory disease, parity, or age at diagnosis (data
not shown).
Discussion
In this large nationwide register-based case-control study,
tubal ligation significantly reduced the risk of overall epi-
thelial ovarian cancer. We found significant risk variation
according to histology with the largest risk reduction
observed for endometrioid ovarian cancer and epithelial
ovarian cancer of “other” histology. In contrast, there was
no association between tubal ligation and risk of border-
line ovarian tumors. Finally, albeit with limited statistical
precision, we observed that bilateral salpingectomy signifi-
cantly reduced the risk of epithelial ovarian cancer by
approximately 40%.
Several hypotheses have been suggested to explain the
inverse association between tubal ligation and ovarian
cancer risk. Tubal ligation may reduce blood flow to the
ovaries and thereby alter levels of growth factors and
Table 2. Risk of epithelial ovarian cancer and histologic subtype by tubal ligation history.
Histologic type of epithelial
ovarian cancer by tubal
ligation history
Cases Controls Age-matched Adjusted
n % n % OR 95% CI OR 95% CIa
All epithelial
No 12 896 97.4 188 488 96.8 ref ref
Yes 345 2.6 6201 3.2 0.81 0.72–0.90 0.87 0.78–0.98
Serous
No 5967 96.9 87 153 96.5 ref ref
Yes 190 3.1 3196 3.5 0.87 0.74–1.01 0.92 0.79–1.08
Mucinous
No 1357 96.0 20 146 96.5 ref ref
Yes 57 4.0 730 3.5 1.18 0.88–1.57 1.25 0.94–1.67
Endometrioid
No 1676 97.8 24 318 96.5 ref ref
Yes 37 2.2 887 3.5 0.60 0.43–0.84 0.66 0.47–0.93
Clear cell
No 611 96.5 8905 95.8 ref ref
Yes 22 3.5 392 4.2 0.82 0.52–1.28 1.03 0.65–1.62
“Other”
No 3285 98.8 47 966 98.0 ref ref
Yes 39 1.2 996 2.0 0.56 0.40–0.77 0.60 0.43–0.83
CI, confidence interval; OR, odds ratio.
aAdjusted for age, parity (0, 1, 2, ≥3), infertility (yes, no), endometriosis (yes, no), pelvic inflammatory disease (yes, no), and hysterectomy (yes, no).
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hormones (8,23,24), or inhibit endometrial tissue or ret-
rograde menstruation ascending from the uterus to the
Fallopian tubes and ovaries (6,8). Moreover, tubal liga-
tion may prevent infection or other carcinogenic agents
(e.g. talc and asbestos) from the external genitalia from
spreading to the Fallopian tubes and ovaries and causing
inflammation (6,8). Finally, it is also suggested that sur-
geons may remove suspicious ovarian tissue during tubal
ligation (6,8). According to the more recent theories on
the origin of epithelial ovarian cancer, endometrioid and
clear cell cancers arise from endometrial cells passing up
through the Fallopian tube (3). Therefore, it has been
hypothesized that tubal ligation is more protective for en-
dometrioid and clear cell tumors compared with the
other histologic subtypes of epithelial ovarian cancer
(5,7).
Consistent with these theories, we observed that tubal
ligation reduced the risk of endometrioid ovarian cancer
substantially and to a greater extent than the risk reduc-
tion for serous cancer. Two previous meta-analyses (5,6)
followed by two large studies (7,9), one of which pooled
data from 13 case–control studies (7), have also reported
the most profound risk reduction for endometrioid can-
cer and similar to our findings, in these studies it was
observed that the magnitude of risk reduction was greater
for endometrioid compared with serous (6,7) or other
subtypes of epithelial ovarian cancer (5,9). Hence, the lit-
erature on tubal ligation and endometrioid cancer seems
to be rather consistent, although in one multicenter case–
control study no association was noted (25). With regard
to clear cell tumors, our study did not confirm the
hypothesis that tubal ligation may have a particularly
strong protective effect. This negative finding is in agree-
ment with one recent study (9), whereas most other stud-
ies reporting risk estimates specifically for clear cell
cancer have described substantial risk reductions associ-
ated with tubal ligation (6,7,25).
Considering the hypothesis that the majority of serous
tumors arise in the Fallopian tube (2–4), it is plausible
that tubal ligation may provide only limited protectionTa
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Table 4. Risk of epithelial ovarian cancer by unilateral and bilateral
salpingectomy.
Salpingectomy
history
Cases
(n)
Controls
(n)
Age-matched Adjusted
OR 95% CI OR 95% CIa
No salping-
ectomy
13 135 192 896 ref ref
Unilateral 89 1382 0.94 0.76–1.18 0.90 0.72–1.12
Bilateral 17 411 0.61 0.37–0.99 0.58 0.36–0.95
CI, confidence interval; OR, odds ratio.
aAdjusted for age, parity (0, 1, 2, ≥3), and tubal ligation.
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against serous ovarian cancer (7,26). In line with this we
found no strong association between tubal ligation and
risk of serous cancer. Although our finding is consistent
with one recent case–control study (9), most previous
data have shown that tubal ligation reduces the risk of
serous cancer (5–7,25). We also observed a substantial
risk reduction of epithelial ovarian cancer of “other” his-
tology. Previous studies have indicated that tubal ligation
reduces risk of this group of epithelial ovarian cancers,
but risk estimates have not been statistically significant
(6,9).
Mucinous ovarian cancer differed from the nonmucin-
ous subtypes as the risk estimate associated with tubal
ligation was >1, although not significantly. Similar find-
ings were also previously reported from Denmark (10)
and America (27). However, the published data on the
association between tubal ligation and mucinous cancer
are inconclusive. Two meta-analyses (5,6) and the one
pooled case–control study (25) reported reduced risk esti-
mates with CIs including 1, whereas in another pooled
case–control study (7) in addition to the study by Rice
et al. (9) significant inverse associations were observed.
One explanation of why the effect of tubal ligation may
vary between mucinous and nonmucinous subtypes of
epithelial ovarian cancer may be their origin, i.e. mucin-
ous tumors are hypothesized to originate from the tubal–
mesothelial junction where the fimbriae touch the perito-
neum (3). Another explanation may be that a proportion
of mucinous ovarian cancers may in fact be metastases
from tumors in the gastrointestinal tract (28).
We also investigated tubal ligation with regard to the
borderline category of epithelial ovarian tumors and in
line with previous studies (5,7,9); we found no associa-
tion between the procedure and risk of borderline ovarian
tumors.
In view of the recent theories on the origin of epithelial
ovarian cancer, it has been proposed that bilateral sal-
pingectomy may represent a potential opportunity for
surgical prevention of serous ovarian cancer (3,12,29).
Although based on limited numbers we did actually
observe that bilateral salpingectomy reduced the risk of
epithelial ovarian cancer by approximately 40%. Unfortu-
nately, our data did not permit subtype-specific analysis.
Interesting data from the Rochester Epidemiology Project
were presented by Lessard-Anderson et al. (30) at the
2013 Annual Meeting of the Society of Gynecologic
Oncology. Based on 29 women (five cases and 24 con-
trols) who had undergone excisional tubal sterilization,
the authors reported that the surgical procedure reduced
the risk of serous ovarian cancer and primary peritoneal
cancer by more than 60% (OR = 0.38; 95% CI 0.14–
1.06). These promising findings require confirmation by
future studies and ideally with a larger sample size. At
best, bilateral salpingectomy could represent a preventive
intervention for women undergoing hysterectomy for
benign disease or requesting permanent contraception or
for women at high genetic risk of ovarian cancer with
ovarian preservation (29,31).
The main strength of our study was that we assessed
tubal ligation and salpingectomy from the National Patient
Register, which eliminated risk of recall bias. Our use of
nationwide registries with virtually complete coverage and
continuously updated data on cancer diagnoses, surgical
procedures and potential confounding factors minimized
selection bias and provided us with data to perform the
largest case–control study on tubal ligation and risk of epi-
thelial ovarian cancer to date and furthermore, to be the
first observational study to publish data on the association
between unilateral and bilateral salpingectomy and epithe-
lial ovarian cancer. Finally, our cases were histologically
verified, which enhanced case validity.
Our study also had some limitations. Although we
included a total of nearly 17 000 cases with epithelial
ovarian cancer or borderline ovarian tumors, the low
Table 5. Risk of borderline ovarian tumor and histologic subtype by tubal ligation history.
Histologic type of epithelial
borderline ovarian tumors by
history of tubal ligation
Cases Controls Age-matched Adjusted
n % n % OR 95% CI OR 95% CIa
All epithelial
No 3414 94.7 50 333 94.4 ref ref
Yes 191 5.3 2989 5.6 0.94 0.81–1.10 1.03 0.89–1.21
Serous
No 1593 94.9 23 408 94.3 ref ref
Yes 86 5.1 1415 5.7 0.89 0.71–1.12 1.00 0.80–1.26
Mucinous
No 1676 94.7 24 751 94.5 ref ref
Yes 94 5.3 1436 5.5 0.97 0.78–1.21 1.04 0.83–1.30
OR, odds ratio.
aAdjusted for age, parity (0, 1, 2, ≥3), infertility (yes, no), endometriosis (yes, no), pelvic inflammatory disease (yes, no), and hysterectomy (yes, no).
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prevalence of tubal ligation and salpingectomy in our
study population limited the statistical precision. In par-
ticular, this limitation may explain why we were unable
to conclude on the effect of timing of tubal ligation and
effect modification by factors other than histology. Infor-
mation on indication for a surgical procedure is not
directly available in the Patient Registry. However,
although not entirely complete, we reviewed the primary
hospital diagnoses registered during the hospital admis-
sion where unilateral or bilateral salpingectomy was per-
formed (as a proxy for surgical indication). Ectopic
pregnancy was by far the most common primary diagno-
sis. Other common diagnoses included salpingitis, oopho-
ritis, hydrosalpinx and benign tumors of the uterus or
ovaries (in our study population, women did not have
salpingectomy in connection with surgery for cancer
because we excluded women with previous cancer and
ignored surgical procedures performed in the year before
index date).
Finally, information on a family history of ovarian and
breast cancer, use of oral contraceptives and hormone
replacement therapy were only available for women born
after 1953. However, sensitivity analysis with additional
adjustment for these factors did not change the overall
risk estimates substantially, indicating that this was not a
major limitation in our study.
Conclusion
Our study confirms that tubal ligation reduces the risk of
epithelial ovarian cancer and particularly endometrioid
ovarian cancer. We observed an even larger risk reduction
of epithelial ovarian cancer associated with bilateral sal-
pingectomy. Additional studies are needed to establish
whether this translates into a potential preventive inter-
vention for epithelial ovarian cancer.
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